PRESS RELEASE

August 10, 2026

Arrowhead Pharmaceuticals Receives Positive Funding Recommendation for REDEMPLO® (plozasiran) from CDA-AMC for Adult Patients with Familial Chylomicronemia Syndrome (FCS)

- Canada's Health Technology Assessment (HTA) agency affirms the clinical value of REDEMPLO to patients with clinically diagnosed or genetically confirmed FCS.

- HTA recommendation marks an important step toward securing public funding for eligible patients in Canada, with provincial and territorial governments ultimately responsible for making the final decision on public coverage.

PASADENA, Calif., August 10, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Canada's Drug Agency / L'Agence des médicaments du Canada (CDA-AMC) has issued final guidance recommending reimbursement with conditions for the use of REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS), diagnosed either by the presence of clinical criteria or genetic testing.[1] Government bodies will consider this recommendation to make final decisions on public coverage for REDEMPLO in individual provinces and territories. This follows Health Canada's approval of REDEMPLO in January 2026.

"FCS is a rare, severe and life-threatening disorder that puts patients at constant risk of debilitating pain and painful pancreatitis attacks.[2] As a leader in Canada's rare disease community, I've spoken with FCS patients and families, and I've seen how unpredictable this disease is to live with, and how many patients spend years searching for answers before they're finally diagnosed," said Durhane Wong-Rieger, President & CEO of Canadian Organization for Rare Disorders. "This treatment represents a positive step forward to support people living with FCS. But innovation only matters if it's accessible to patients. We are encouraged to see this reimbursement recommendation from the CDA-AMC, and remain grateful to Arrowhead for bringing this life-changing therapy to our Canadian FCS families."

“This is important progress for people whose lives are profoundly affected by FCS. The recommendation to reimburse an additional treatment option, together with a more flexible diagnostic approach that recognizes FCS based on either a clinical diagnosis or genetic confirmation, represents a meaningful step forward,” said Daniel Gaudet, M.D., Ph.D., a principal investigator in the PALISADE clinical study, which supported the committee’s unanimous recommendation. “The committee’s recognition of a shared-care model is particularly important, given the limited number of academic lipid clinics and lipid specialists with expertise in FCS across Canada. This approach could allow patients to receive ongoing care and monitoring from their local physician and multidisciplinary care team, with virtual consultations with an expert prescriber when appropriate.”

Full details of the reimbursement recommendation, including clinical criteria and conditions, can be accessed on the CDA-AMC website. Assessment by the Institut national d’excellence en santé et en services sociaux (INESSS) is in progress, covering reimbursement in Quebec. Discussions around coverage through private payers are also ongoing.

“We are pleased to have received this positive recommendation for public coverage of REDEMPLO for people living with FCS in Canada,” added Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We will continue our active engagement with regional government bodies as well as with private providers, with the aim for securing broad access to REDEMPLO for eligible patients across Canada.”

About Familial Chylomicronemia Syndrome (FCS)

Familial chylomicronemia syndrome (FCS) is a severe and rare disease leading to extremely high triglyceride (TG) levels, typically over 880 mg/dL (9.94 mmol/L).[3] Such severe elevations can lead to various serious signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues. Currently, there are limited therapeutic options to adequately treat FCS.

About REDEMPLO® (plozasiran)

REDEMPLO (plozasiran) is approved by Health Canada as an adjunct to diet to reduce triglycerides for adults with Familial Chylomicronemia Syndrome (FCS).[3] It is also approved with similar indications in the U.S.A., China, Australia and the European Economic Area. REDEMPLO is a siRNA therapeutic drug designed to suppress the production of apolipoprotein C-III (apoC-III), a protein produced primarily in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting apoC-III with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is the

first and only siRNA treatment approved by regulatory bodies that has been studied in both genetically confirmed and clinically diagnosed patients living with FCS.

For more information about REDEMPLO, see the full Product Monograph.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we aim to rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.

For more information, please visit www.arrowheadpharma.com, or follow us on LinkedIn.

References

1. Canada's Drug Agency – L'Agence des médicaments du Canada (CDA-AMC), Reimbursement Recommendation Plozasiran (Redemplo) (Final), available via https://www.cda-amc.ca/plozasiran [Accessed August 2026].
2. Davidson M, Stevenson M, et al. *J Clin Lipidol.* 2018;12(4):898-907.e2.
3. Arrowhead Pharmaceuticals Inc. (2026) Redemplo Canadian product monograph, available via https://arrowheadpharma.com/en-ca/redemplo/product-monograph.pdf [Accessed August 2026].

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidates or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about our beliefs and expectations regarding the long-term impacts of REDEMPLO (plozasiran) on patient health and the health care system; our beliefs and expectations regarding the pricing, value, or expected timing for availability of our drugs and drug candidates if approved; and our beliefs and expectations around the potential uses and value of the TRiM™ platform. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products if approved, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing

clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Contacts:

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
+1 626-304-3400
ir@arrowheadpharma.com

Investors:
LifeSci Advisors, LLC
Brian Ritchie
+1 212-915-2578
britchie@lifesciadvisors.com

Media:
HAVAS PR – Europe / Canada
Andrew Smith
+44 7760 883 315
andrew.smith@havas.com

HAVAS PR – U.S.
Jacqueline Wickwire
+1 617-901-2854
Jacqueline.wickwire@havasred.com

Source: Arrowhead Pharmaceuticals, Inc.

_____

MAT-1089-v2.0-08/2026

# # #